At the Cold Spring Harbor Laboratory Conference on Blood-Brain Barriers, Dr. Sylvaine Guerit (Head of Preclinical Research) will…
Atti25 March 2025
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers.
This groundbreaking approach holds the potential to transform treatments and improve the lives of patients with vascular retinopathies – diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) – or severe neurological disorders.
More about our science
Advancing innovative Wnt surrogate antibodies
to restore blood-CNS barriers
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers.
This groundbreaking approach holds the potential to transform treatments and improve the lives of patients with vascular retinopathies – diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) – or severe neurological disorders.
More about our science
Join us in our mission to develop innovative therapies that truly impact patients’ lives
Latest insights and highlights
Latest insights and highlights
At the Cold Spring Harbor Laboratory Conference on Blood-Brain Barriers, Dr. Sylvaine Guerit (Head of Preclinical Research) will…
Atti25 March 2025
Neuvasq will participate in the Bio-Neuroscience Summit 2025 in Amsterdam, a dedicated forum for innovation, partnering and…
buro867 February 2025
Neuvasq Biotechnologies participated in the 2025 J.P. Morgan Healthcare Conference, a key event in the global…
buro8628 January 2025
Cookie policy